Light-Activated Molecular Cages Could Target Protein-Destroying Drugs

Scientists have developed a novel molecular cage that can keep protein-degrading drugs inactive until exposed to low-energy red light, offering a potential breakthrough in precision medicine. The technology, named RuPHOTACs, allows researchers to control when and where these powerful molecules become active, minimizing damage to healthy tissues. This approach could lead to safer treatments for diseases driven by specific proteins, such as certain cancers. By using light as a trigger, the system provides spatial and temporal control over drug activity, a key challenge in targeted therapy. The findings, published in a peer-reviewed journal, highlight a step toward more selective and less toxic treatments. As research progresses, light-activated cages may become a valuable tool in the development of next-generation therapeutics.